Search results for " exacerbation"

showing 10 items of 41 documents

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life

2020

Background: Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We evaluated MEP efficacy on lung function, symptoms, asthma exacerbations, biologic markers, steroid dependence and controller treatment level in real-life. Methods: We retrospectively analyzed 134 severe asthmatics (61 males; mean age 58.3 ± 11; mean FEV1%:72 ± 21), treated with MEP for at least 6 months (mean duration:10.9 ± 3.7 months). Results: FEV1% improved significantly after MEP. Mean FEF25-75 also increased from 37.4 ± 25.4% to 47.2 ± 27.2% (p < 0.0001). Mean baseline blood eosinophil level was 712 ± 731/μ…

MaleOmalizumabFEF(25-75)step-down0302 clinical medicineMaintenance therapyAdrenal Cortex HormonesSettore MED/10Pharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicinesmall airwaysAsthma exacerbationsmepolizumabMiddle AgedAnesthesiaFEF25-75CorticosteroidDrug Therapy CombinationFemalemedicine.drugPulmonary and Respiratory Medicinesevere asthmamedicine.drug_classMepolizumab Severe asthma Real-life Small airways FEF25-75 Oral corticosteroids Step-down EffectiveneseffectivenessSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroidsAntibodies Monoclonal HumanizedNO03 medical and health sciencesEffectiveness FEF 25-75 Mepolizumab Oral corticosteroids Real-life Severe asthma Small airways Step-downmedicineHumansIn real lifeFEFreal-lifeAgedRetrospective StudiesBiologic markerbusiness.industryEffectivenesBiochemistry (medical)Effectiveness; FEF; 25-75; Mepolizumab; Oral corticosteroids; Real-life; Severe asthma; Small airways; Step-downAirway obstructionmedicine.diseaseAsthmaBlood Cell Countrespiratory tract diseasesAirway ObstructionEosinophils030228 respiratory systemeffectiveness; FEF(25-75); mepolizumab; oral corticosteroids; real-life; severe asthma; small airways; step-down25-75businessMepolizumab
researchProduct

Upregulation of activin-B and follistatin in pulmonary fibrosis: a translational study using human biopsies and a specific inhibitor in mouse fibrosi…

2014

Background: Activins are members of the TGF-ß superfamily of growth factors. First, we identified by expression array screening that activin-B and follistatin are upregulated in human idiopathic pulmonary fibrosis (IPF). Next, we wanted to clarify their specific role in lung fibrosis formation. Methods: We used specific antibodies for activin-A and -B subunits and follistatin to measure and localize their levels in idiopathic pulmonary fibrosis and control lung biopsies. To inhibit activin signaling, we used soluble activin type IIB receptor fused to the Fc portion of human IgG1 (sActRIIB-Fc) in two different mouse models of pulmonary fibrosis. Results: Activin-B and follistatin mRNA levels…

MalePathologyFollistatinPulmonary FibrosisPROTEINCell CountQuadriceps MuscleACTIVATIONIdiopathic pulmonary fibrosisMiceBMP-7FibrosisPulmonary fibrosisfollistatinInhibin-beta SubunitsGREMLINImmunity Cellularmedicine.diagnostic_testbiologyactivinsPIRFENIDONEPirfenidonerespiratory systemidiopathic pulmonary fibrosisMouse fibrosis model3. Good healthUp-RegulationActivinsmedicine.anatomical_structureACUTE EXACERBATIONmouse fibrosis modelembryonic structuresGROWTHBronchoalveolar Lavage Fluidhormones hormone substitutes and hormone antagonistsmedicine.drugResearch ArticleSignal TransductionPulmonary and Respiratory MedicineEXPRESSIONmedicine.medical_specialtyendocrine systemRecombinant Fusion ProteinseducationIdiopathic pulmonary fibrosisRespiratory MucosaAlveolar cellsINFLAMMATIONmedicineAnimalsHumansRNA MessengerLungbusiness.industrymedicine.diseaserespiratory tract diseasesMice Inbred C57BLPulmonary AlveoliDisease Models AnimalBronchoalveolar lavageProtein Biosynthesis3121 General medicine internal medicine and other clinical medicinebiology.proteinbusinessFollistatin
researchProduct

Assessing biomarkers in a real-world severe asthma study (ARIETTA)

2016

AbstractThe prognostic value of asthma biomarkers in routine clinical practice is not fully understood. ARIETTA (NCT02537691) is an ongoing, prospective, longitudinal, international, multicentre real-world study designed to assess the relationship between asthma biomarkers and disease-related health outcomes. The trial aims to enrol and follow for 52 weeks approximately 1200 severe asthma patients from approximately 160 sites in more than 20 countries. Severe asthmatics, treated with daily inhaled corticosteroid (≥500 μg of fluticasone propionate or equivalent) and at least 1 second controller medication are to be included. In this real-world study, patients will be treated according to the…

MaleSevere asthmaCardiac & Cardiovascular SystemsExacerbationAIRWAY INFLAMMATIONRespiratory SystemEosinophilSeverity of Illness Indexlaw.inventionDOUBLE-BLIND0302 clinical medicineQuality of lifeRandomized controlled trialAdrenal Cortex HormoneslawForced Expiratory VolumeProspective Studies030212 general & internal medicineProspective cohort studyFluticasoneEPITHELIAL-CELLSExacerbationRANDOMIZED CONTROLLED-TRIALPrognosis3. Good healthTO-SEVERE ASTHMAFemaleLife Sciences & Biomedicinemedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyPHENOTYPESNitric Oxide1102 Cardiovascular Medicine And HaematologyFluticasone propionate03 medical and health sciencesPredictive Value of TestsAdministration InhalationSeverity of illnessmedicineHumansNITRIC-OXIDE SYNTHASEIntensive care medicineCOMBINATIONAsthmaScience & Technologybusiness.industryPULMONARY-FUNCTION1103 Clinical SciencesBiomarkerImmunoglobulin Emedicine.diseaseAsthmarespiratory tract diseasesEosinophilsBiomarker; Eosinophil; Exacerbation; Periostin; Severe asthma; Pulmonary and Respiratory MedicinePeriostin030228 respiratory systemQuality of LifeCardiovascular System & CardiologyFluticasonebusinessCell Adhesion MoleculesBiomarkersRespiratory Medicine
researchProduct

Lipoxygenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease

2011

Background and Objective. Chronic obstructive pulmonary disease (COPD) is characterized by a persistence of inflammation in large and small airways. We hypothesized that this could be caused by the inability of an inflammatory process to resolve. In the resolution of inflammation, a switching of arachidonic acid metabolism from the production of proinflammatory leukotriene B4 (LtB4) to the synthesis of anti-inflammatory lipoxins plays an important role. The aim of our study was to determine the content of lipoxin A4 (LXA4) and LtB4 in induced sputum of patients with exacerbated COPD and to compare it to healthy controls, as well as to analyze the relationship between proinflammatory and ant…

MaleSputum CytologyExacerbationLeukotriene B4InflammationLeukotriene B4Proinflammatory cytokinePulmonary Disease Chronic Obstructivechemistry.chemical_compoundHumansMedicineCOPDbusiness.industrySputumGeneral MedicineMiddle Agedmedicine.diseaserespiratory tract diseasesLipoxinschemistrychronic obstructive pulmonary disease; exacerbation; lipoxin A<sub>4</sub>; leukotriene B<sub>4</sub>ImmunologyAbsolute neutrophil countSputumFemalelipids (amino acids peptides and proteins)medicine.symptombusiness
researchProduct

Unlocking the limitations: Living with chronic obstructive pulmonary disease and receiving care through telemedicine-A phenomenological study

2017

Aims and objectives To describe the lived experiences of quality of life among a group of patients living with chronic obstructive pulmonary disease who were included in a telemedical intervention after hospitalisation for disease exacerbation. Background Patients with chronic obstructive pulmonary disease have high symptom burden, poor control of symptoms and a need for greater requirements in care. Telemedicine can provide benefits for patients with chronic obstructive pulmonary disease by improving self-management. Design Descriptive phenomenological approach. Methods Ten in-depth interviews were conducted with chronic obstructive pulmonary disease patients participating in a telemedical…

MaleTelemedicinemedicine.medical_specialtyPulmonary diseaseSeverity of Illness IndexInterviews as TopicPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineNursingAdaptation PsychologicalPatient experienceHealth caremedicineHumansDisease Exacerbation030212 general & internal medicineIntensive care medicineGeneral NursingAgedAged 80 and overSelf-managementbusiness.industrySelf-ManagementLived experienceSymptom burdenGeneral MedicineMiddle AgedTelemedicine030228 respiratory systemQuality of LifeFemalebusinessJournal of Clinical Nursing
researchProduct

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct

A year in the life of German patients with COPD: the DACCORD observational study

2016

Roland Buhl,1 Carl-Peter Cri&amp;eacute;e,2 Peter Kardos,3 Claus Vogelmeier,4,5 Nadine Lossi,6 Claudia Mail&amp;auml;nder,6 Heinrich Worth7 1Pulmonary Department, Mainz University Hospital, Mainz, 2Department of Sleep and Respiratory Medicine, Evangelical Hospital G&amp;ouml;ttingen-Weende, Bovenden, 3Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main, 4Department of Medicine, Pulmonary, and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, 5German Center for Lung Research, Marburg, 6Clinical Research Primary Care, Novartis Pharma GmbH, N&amp;uuml;rnberg, 7Facharztforum F&amp;…

Malemedicine.medical_specialtyPediatricsTime FactorsPulmonary diseaseDiseaseInternational Journal of Chronic Obstructive Pulmonary DiseaseSeverity of Illness IndexSecondary CareSecondary careGerman03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineAmbulatory careRisk FactorsForced Expiratory VolumeGermanyEpidemiologymedicineCOPDHumans030212 general & internal medicineLongitudinal StudiesProspective StudiesLungOriginal ResearchAgedCOPDPrimary Health Carebusiness.industryGeneral MedicineMiddle Agedmedicine.diseaselanguage.human_languageBronchodilator AgentsTreatment Outcome030228 respiratory systemCOPD exacerbationsSpirometryEmergency medicinelanguageDisease ProgressionObservational studyepidemiologybusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Inspiratory Effort and Respiratory Mechanics in Patients with Acute Exacerbation of Idiopathic Pulmonary fibrosis: A Preliminary Matched Control Stud…

2022

Background: Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) may experience severe acute respiratory failure, even requiring ventilatory assistance. Physiological data on lung mechanics during these events are lacking. Methods: Patients with AE-IPF admitted to Respiratory Intensive Care Unit to receive non-invasive ventilation (NIV) were retrospectively analyzed. Esophageal pressure swing (ΔPes) and respiratory mechanics before and after 2 hours of NIV were collected as primary outcome. The correlation between positive end-expiratory pressure (PEEP) levels and changes of in dynamic compliance (dynCRS) and PaO2/FiO2 ratio was assessed. Further, an exploratory compar…

Pulmonary and Respiratory MedicineAcute exacerbation of idiopathic pulmonary fibrosiEsophageal pressure swingEsophageal manometryARDSNon-invasive mechanical ventilationInspiratory effortRespiratory mechanics.Acute respiratory failureDynamic transpulmonary pressurePulmonology
researchProduct

Asthma exacerbations and socio-economic status in French adults with persistent asthma: A prospective cohort study.

2017

Adults disadvantaged by poor socio-economic status (SES) are more severely affected by asthma compared to those with better SES. We aimed to determine whether the frequency of asthma exacerbations (AEx), as well as aspects related to AEx management, differed based on SES in patients treated with daily treatments.This study, part of the prospective observational cohort ASTRO-LAB, included French adult patients with persistent asthma. Patients were considered as low SES if they benefited from publicly funded special health insurance and/or were perceived as low SES by their general practitioner. AEx was defined as at least one of the following: asthma-related oral corticosteroid course, medic…

Pulmonary and Respiratory MedicineAdultHypersensitivity ImmediateMalePediatricsmedicine.medical_specialtyAdolescentGeneral PracticeComorbiditySeverity of Illness IndexBody Mass Index03 medical and health sciencesYoung Adult0302 clinical medicineImmunology and AllergyMedicineHumans030212 general & internal medicineSocial determinants of healthAnti-Asthmatic AgentsProspective StudiesProspective cohort studySocioeconomic statusAsthmaAsthma exacerbationsMedical Assistancebusiness.industrysocial sciencesmedicine.diseaseAsthma030228 respiratory systemSocioeconomic FactorsPediatrics Perinatology and Child HealthCohortpopulation characteristicsObservational studyFemaleFrancebusinessEmergency Service HospitalCohort studyThe Journal of asthma : official journal of the Association for the Care of Asthma
researchProduct

Sociodemographic factors associated with time to discharge for hospitalised patients with asthma and asthma exacerbation using the Ghana Health Servi…

2021

ObjectiveData on asthma hospitalisations are a useful source of patient morbidity information. In Ghana, the length of stay (LoS) and sociodemographic factors of patients hospitalised for asthma and its exacerbation are understudied. We aimed to investigate the time to discharge and assessed factors associated with length of hospital stays of asthmatics in Ghana.MethodsRetrospective analysis of hospitalised patient with asthma records between 2012 and 2017 from the nationwide Ghana Health Service District Health Information Management System 2 database. We calculated the cumulative incidence function for discharge stratified by age group and sex. Multivariable Cox regression was used to inv…

Pulmonary and Respiratory MedicineAdultSociodemographic FactorsExacerbationInformation Managementcomputer.software_genreGhanaHealth servicesDiseases of the respiratory systemHealth caremedicineHumans1506ChildEarly dischargeAsthmaRetrospective StudiesAsthma exacerbationsDatabaseRC705-779business.industryProportional hazards modelasthma epidemiologyRmedicine.diseaseComorbidityAsthmaPatient DischargeCOPD exacerbationsMedicineFemalebusinesscomputerBMJ Open Respiratory Research
researchProduct